Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yutaka Shimazu

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|February 19, 2025
Edoxaban for Atrial Fibrillation and Stable Coronary Artery DiseaseYutaka Shimazu
Lancet (London, England)|April 5, 2025
PET evaluation in Hodgkin lymphoma: when to change treatmentYutaka Shimazu
Hematological Oncology|March 24, 2017
Existence of JAK2 mutation 19 years prior to the development of overt polycythemia veraYutaka Shimazu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2026
Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line TherapyYutaka Shimazu
Lancet (London, England)|November 1, 2025
Stratifying IL-2 therapy in ALS: integrating biomarkersYutaka Shimazu
The New England Journal of Medicine|April 11, 2025
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis RiskYutaka Shimazu
Lancet (London, England)|October 18, 2025
Glofitamab with GemOx for diffuse large B-cell lymphomaYutaka Shimazu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2024
Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic MalignanciesYutaka Shimazu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2025
Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR MatchingYutaka Shimazu
Annals of Hematology|April 6, 2017
Idiopathic hypereosinophilic syndrome manifesting with eosinophilic cholecystitis and recurrent gastroenteritisYutaka Shimazu, Hiromitsu Nagata
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|February 19, 2025
Edoxaban for Atrial Fibrillation and Stable Coronary Artery DiseaseYutaka Shimazu
Lancet (London, England)|April 5, 2025
PET evaluation in Hodgkin lymphoma: when to change treatmentYutaka Shimazu
Hematological Oncology|March 24, 2017
Existence of JAK2 mutation 19 years prior to the development of overt polycythemia veraYutaka Shimazu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2026
Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line TherapyYutaka Shimazu
Lancet (London, England)|November 1, 2025
Stratifying IL-2 therapy in ALS: integrating biomarkersYutaka Shimazu
The New England Journal of Medicine|April 11, 2025
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis RiskYutaka Shimazu
Lancet (London, England)|October 18, 2025
Glofitamab with GemOx for diffuse large B-cell lymphomaYutaka Shimazu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2024
Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic MalignanciesYutaka Shimazu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2025
Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR MatchingYutaka Shimazu
Annals of Hematology|April 6, 2017
Idiopathic hypereosinophilic syndrome manifesting with eosinophilic cholecystitis and recurrent gastroenteritisYutaka Shimazu, Hiromitsu Nagata
Pageof 7